Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-25-080266
Filing Date
2025-08-19
Accepted
2025-08-19 16:17:14
Documents
2
Period of Report
2025-08-15

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2523826-4_4seq1.html 4  
1 OWNERSHIP DOCUMENT tm2523826-4_4seq1.xml 4 3774
2 EXHIBIT 24.1 tm2523826d4_ex24-1.htm EX-24.1 9007
  Complete submission text file 0001104659-25-080266.txt   14523
Mailing Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666
Business Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666 201-329-7300
PHIBRO ANIMAL HEALTH CORP (Issuer) CIK: 0001069899 (see all company filings)

EIN.: 131840497 | State of Incorp.: DE | Fiscal Year End: 0630
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 300 FRANK W. BURR BOULEVARD SUITE 21 TEANECK NJ 07666
Business Address
Bendheim Daniel M (Reporting) CIK: 0001601576 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36410 | Film No.: 251232019